Description
Retatrutide (often referred to as “GLP-3”) is an experimental triple-hormone receptor agonist being developed by Eli Lilly that activates GLP-1, GIP, and glucagon receptors. Clinical trials show it drives average weight loss of up to 24% to 28% and significant blood sugar reduction
https://janoshik.com/tests/96858-R50_yellow_cap_V4TE2ZGIIUEY
Reviews
There are no reviews yet.